



To the Copenhagen Stock Exchange  
Announcement No. 09-07 / Copenhagen, 12 April 2007

**TopoTarget A/S**  
Symbion  
Fruebjergvej 3  
DK 2100 Copenhagen  
Denmark  
Tel: +45 39 17 83 92  
Fax: +45 39 17 94 92  
CVR-nr: 25695771

[www.topotarget.com](http://www.topotarget.com)

## **Proceedings at the annual general meeting of TopoTarget A/S**

The company's annual general meeting was held on Wednesday, 11 April 2007, as per the notice convening the meeting dated 27 March 2007.

Note was taken of the Chairman's and the CEO's reports and the financial statements for 2006 were unanimously adopted by the shareholders at the general meeting.

The Board of Directors' proposal to carry the loss for the year of DKK 106.2 million forward to next year was unanimously adopted.

The proposal by the Board of Directors to authorise the acquisition of treasury shares by the Board was unanimously adopted.

Also, the Board of Directors' proposal to authorise the Board to issue up to a total of 1,000,000 warrants, each entitling the holder to subscribe for one share of DKK 1 nominal value, and to make the relevant capital increases, was unanimously adopted. The authorisation will be included as a new article 6a in the company's articles of association and is expected to be registered with the Danish Commerce and Companies Agency as soon as possible.

All members of TopoTarget's Board of Directors were re-elected.

Deloitte was re-appointed as TopoTarget's auditors.

### **TopoTarget A/S**

For further information, please contact:

Dr. Peter Buhl Jensen Chief Executive Officer	Telephone Mobile	+45 39 17 83 41 +45 21 60 89 22
Leif Hamø Chief Financial Officer	Telephone Mobile	+45 39 17 83 45 +45 40 33 40 83



## Background information

### About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to [Hwww.topotarget.com.H](http://Hwww.topotarget.com.H)

### TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

